A retrospective study evaluating pembrolizumab, pomalidomide and dexamethasone combination therapy in pre-treated pomalidomide exposed patients with relapsed or refractory multiple myeloma

Trial Profile

A retrospective study evaluating pembrolizumab, pomalidomide and dexamethasone combination therapy in pre-treated pomalidomide exposed patients with relapsed or refractory multiple myeloma

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Pomalidomide (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Jan 2017 New trial record
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top